LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC) announced today it has appointed David L. Katz, MD, MPH, FACPM, FACP, FACLM - CEO of Diet ID, Inc, founder and former director of Yale University’s Yale-Griffin Prevention Research Center and past president of the American College of Lifestyle Medicine, to its Scientific Advisory Board (SAB). Dr. Katz is a leading expert in nutrition, health promotion and the prevention of chronic disease through his work as a researcher, author and clinician.
As CEO of Diet ID, Dr. Katz oversees a team working to make diet a vital sign, leveraging an advance in dietary assessment. He also serves as president for True Health Initiative, a non-profit organization that he established to defend and disseminate the science, sense, and global expert consensus about healthy, sustainable diet and lifestyle in the service of “adding years to lives and life to years around the globe.”
Dr. Katz earned his B.A. degree from Dartmouth College, his M.D. from the Albert Einstein College of Medicine and his M.P.H. from the Yale University School of Public Health. Katz completed sequential residency training in Internal Medicine and Preventive Medicine/Public Health, earning board certification in both disciplines. He provided care to patients in an academic practice model for nearly 30 years.
“We are honored that Dr. Katz has agreed to join our distinguished board of scientific advisors,” said ChromaDex CEO Rob Fried. “His background as a world renowned clinician and researcher complements those of the existing members in our mission to understand the many ways NAD+ and NR can improve human health.”
“It is a privilege to join the ChromaDex Scientific Advisory Board, a company that has made formidable strides toward improving healthspans,” said Dr. Katz. “I look forward to working with world-leading scientists to deepen our knowledge on how NAD+ and lifestyle interventions can support the aging population.”
Dr. Katz is credited with inventing multiple research methods and clinical trial approaches for preventive medicine. Notably, he developed “evidence mapping,” a research method that describes the level of research done in a broad topic of medicine and how that research is distributed. Evidence mapping has since been adopted by the World Health Organization. He also created a clinical trial approach called the multi-site translational community trial (MTCT), which bridges the gap between what a clinical trial theoretically demonstrates can work versus what is needed to make it effective in real-world settings. Most recently, he designed “evidence threshold pathway mapping,” a method dedicated to understanding lifetime effects of health behaviors.
Recognized by peers as the “poet laureate of health promotion,” Dr. Katz has delivered talks in all 50 states and in countries on six continents. He has served as an on-air medical contributor for Good Morning America/ABC News, has been recognized with three honorary doctorate degrees, and was a finalist for a James Beard Foundation Award in 2019 for health journalism pieces in New York magazine. He has published 18 books and more than 200 scientific articles and textbook chapters.
For additional information about ChromaDex, please visit www.chromadex.com.
ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex delivers Niagen® as the sole active ingredient in its consumer product Tru Niagen® available at www.truniagen.com and through partnerships with global retailers and distributors. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 as amended, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.